UK researchers have launched a study to assess the potential benefits of whole-genome sequencing in primary health care.
Institute of Cancer Research professor Ros Eeles and 90 Sloane Street general practitioner Michael Sandberg will lead the initiative, 90S Study.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Patient volunteers from 90 Sloane Street will be recruited for the study.
Furthermore, the study will involve experts of The Institute of Cancer Research (ICR) and The Royal Marsden, as well as cardiologists of Royal Brompton Hospital.
The study will be conducted under the lead of 90 Sloane Street Genetic centre, a collaborative team of five consultant geneticists.
If the study is successful, it could mean a significant step towards the regular use of genetic testing to manage the future health of patients in the NHS.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataInitially, 20 patients will be studied to monitor the physiological effects of genome screening as part of a study funded by donations to the ICR.
The study will have support from the NIHR Biomedical Research Centre at The Royal Marsden and the ICR and 90 Sloane Street.
The study will later be expanded to around 1,000 patients, who will be initially recruited at 90 Sloane Street and then at NHS GP practices.
Under the initiative, researchers will evaluate the complete genetic code of those attending a GP surgery, reporting on around 600 separate genetic changes linked with disease and how patients respond to or metabolise some medicines.
The study is looking for ‘actionable gene alterations’ and if identified, it would require a change in choices for an individual such as lifestyle improvements, specific screening and targeted treatments.
